Abstract: The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport and electrical conductance.

Abstract: The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in inhibiting cholesterol-induced cytochrome c peroxidase activity, promoting reduction of cytochrome c, and inhibition of cardiolipin peroxidation to treat, prevent or ameliorate cholesterol-induced mitochondrial dysfunction.

Abstract: The present disclosure provides aromatic-cationic peptides and methods of using the same. The methods comprise the use of the aromatic-cationic peptides in reducing the effects of toxic beta amyloid (A?) peptides including blocking the accumulation of extracellular A? oligomers, inhibiting A?-mediated oxygenase activity, reducing A?-induced mitochondrial dysfunction and/or preventing A?-induced neuronal apoptosis.

Abstract: The present disclosure provides aromatic-cationic peptide compositions and methods of using the same. The methods comprise use of the peptides in electron transport and electrical conductance.

Abstract: A Metabolic Enhancement Therapy nutritional supplement for treating symptoms and conditions such as acute anxiety, hyperactivity, panic attacks, confusion, involuntary movements, sleep disorders, mood disorders, depression, anger, seizures, obsessive-compulsive behavior, unregulated fear, panic, neuronal disorders, autism, schizophrenia, attention deficit disorder (ADD), attention deficit hyperactive disorder (ADHD) and neuronally based immunologic disorders by administering to a mammal an effective amount of acetyl-L-carnitine, ?-lipoic acid, biotin, vitamin B1, L-glutamine, Vitamin B6, taurine, folinic acid, vitamin B12, trimethylglycine, and L-tryptophan.

Abstract: The present invention is directed to compounds, compositions and methods comprising the aminoglycoside moiety represented by Formula II for treating and preventing the spread of positive sense single-stranded RNA envelope viral infections. One embodiment of the present invention uses geneticin or its analogs, including 2-amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranose, as the antiviral agent. The compounds, compositions and methods of the present invention are applicable to infections resulting from Hepatitis C virus, West Nile virus, Yellow Fever virus, Dengue virus, Bovine Viral Diarrhea virus, Equine Arteritis virus, and/or Sindbis virus.